Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Gene editing in the context of an increasingly complex genome.

Blighe K, DeDionisio L, Christie KA, Chawes B, Shareef S, Kakouli-Duarte T, Chao-Shern C, Harding V, Kelly RS, Castellano L, Stebbing J, Lasky-Su JA, Nesbit MA, Moore CBT.

BMC Genomics. 2018 Aug 8;19(1):595. doi: 10.1186/s12864-018-4963-8. Review.

2.

Harms of cigarette smoking: call to increase knowledge among children.

Lonergan B, Harding V, Cohen H, Wylleman E, Cohen R, Stebbing J.

Eur J Cancer Prev. 2019 Jan;28(1):54-57. doi: 10.1097/CEJ.0000000000000409.

3.

Liquorice: a treatment for all sorts?

Harding V, Stebbing J.

Lancet Oncol. 2017 Sep;18(9):1155. doi: 10.1016/S1470-2045(17)30628-9. No abstract available.

4.

The need for multidisciplinarity in specialist training to optimize future patient care.

Tree AC, Harding V, Bhangu A, Krishnasamy V, Morton D, Stebbing J, Wood BJ, Sharma RA.

Nat Rev Clin Oncol. 2017 Aug;14(8):508-517. doi: 10.1038/nrclinonc.2016.185. Epub 2016 Nov 29. Review.

PMID:
27898067
5.

Oil residue contamination of continental shelf sediments of the Gulf of Mexico.

Harding V, Camp J, Morgan LJ, Gryko J.

Mar Pollut Bull. 2016 Dec 15;113(1-2):488-495. doi: 10.1016/j.marpolbul.2016.07.032. Epub 2016 Jul 29.

PMID:
27477068
6.
7.

LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5.

Jacob J, Favicchio R, Karimian N, Mehrabi M, Harding V, Castellano L, Stebbing J, Giamas G.

Cancer Lett. 2016 Mar 1;372(1):137-46. doi: 10.1016/j.canlet.2015.12.026. Epub 2015 Dec 29.

PMID:
26739063
8.

TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network.

Krell J, Stebbing J, Carissimi C, Dabrowska AF, de Giorgio A, Frampton AE, Harding V, Fulci V, Macino G, Colombo T, Castellano L.

Genome Res. 2016 Mar;26(3):331-41. doi: 10.1101/gr.191759.115. Epub 2015 Dec 23.

9.

The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNA-mRNA interaction network.

Krell J, Stebbing J, Frampton AE, Carissimi C, Harding V, De Giorgio A, Fulci V, Macino G, Colombo T, Castellano L.

Lancet. 2015 Feb 26;385 Suppl 1:S15. doi: 10.1016/S0140-6736(15)60330-0.

PMID:
26312837
10.

The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.

Badreldin W, Krell J, Chowdhury S, Harland SJ, Mazhar D, Harding V, Frampton AE, Wilson P, Berney D, Stebbing J, Shamash J.

BJU Int. 2016 Mar;117(3):418-23. doi: 10.1111/bju.13004. Epub 2015 Jun 13.

11.

Noncoding RNAs and the control of hormonal signaling via nuclear receptor regulation.

Ottaviani S, de Giorgio A, Harding V, Stebbing J, Castellano L.

J Mol Endocrinol. 2014 Oct;53(2):R61-70. doi: 10.1530/JME-14-0134. Epub 2014 Jul 25. Review.

PMID:
25062739
12.

Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer.

Krell J, Frampton AE, Mirnezami R, Harding V, De Giorgio A, Roca Alonso L, Cohen P, Ottaviani S, Colombo T, Jacob J, Pellegrino L, Buchanan G, Stebbing J, Castellano L.

PLoS One. 2014 Jun 13;9(6):e98561. doi: 10.1371/journal.pone.0098561. eCollection 2014.

13.

The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy.

Stebbing J, Harding V, Urch CE, Kaier T, Schofield G, Flook M, Alifrangis C, Young AM, Shaw JA, Coombes RC, Krell J.

Future Oncol. 2014 Dec;10(16):2555-60. doi: 10.2217/FON.14.107.

14.

Patient-derived xenografts for individualized care in advanced sarcoma.

Stebbing J, Paz K, Schwartz GK, Wexler LH, Maki R, Pollock RE, Morris R, Cohen R, Shankar A, Blackman G, Harding V, Vasquez D, Krell J, Zacharoulis S, Ciznadija D, Katz A, Sidransky D.

Cancer. 2014 Jul 1;120(13):2006-15. doi: 10.1002/cncr.28696. Epub 2014 Apr 4. Erratum in: Cancer. 2014 Nov 15;120(22):3588. Zacharoulis, Stergios [added].

15.

Brain metastases associated with germ cell tumors may be treated with chemotherapy alone.

Hardt A, Krell J, Wilson PD, Harding V, Chowdhury S, Mazhar D, Berney D, Stebbing J, Shamash J.

Cancer. 2014 Jun 1;120(11):1639-46. doi: 10.1002/cncr.28629. Epub 2014 Mar 25.

16.

Crystals and cancer: good vibrations or bad intentions?

Harding V, Stebbing J.

Lancet Oncol. 2014 Mar;15(3):263-4. doi: 10.1016/S1470-2045(14)70098-1. No abstract available.

PMID:
24599925
17.

Novel cancer therapies: treatments driven by tumour biology.

Ramaswami R, Harding V, Newsom-Davis T.

Postgrad Med J. 2013 Nov;89(1057):652-8. doi: 10.1136/postgradmedj-2012-131533. Review.

PMID:
24129032
18.

MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression.

Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J, Jacob J, Pellegrino L, Roca-Alonso L, Funel N, Gall TM, De Giorgio A, Pinho FG, Fulci V, Britton DJ, Ahmad R, Habib NA, Coombes RC, Harding V, Knösel T, Stebbing J, Jiao LR.

Gastroenterology. 2014 Jan;146(1):268-77.e18. doi: 10.1053/j.gastro.2013.10.010. Epub 2013 Oct 9.

PMID:
24120476
19.

'Being there' for women with metastatic breast cancer: a pan-European patient survey.

Harding V, Afshar M, Krell J, Ramaswami R, Twelves CJ, Stebbing J.

Br J Cancer. 2013 Sep 17;109(6):1543-8. doi: 10.1038/bjc.2013.492. Epub 2013 Sep 3.

20.

Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation.

Pinho FG, Frampton AE, Nunes J, Krell J, Alshaker H, Jacob J, Pellegrino L, Roca-Alonso L, de Giorgio A, Harding V, Waxman J, Stebbing J, Pchejetski D, Castellano L.

Cancer Res. 2013 Oct 1;73(19):5936-48. doi: 10.1158/0008-5472.CAN-13-0158. Epub 2013 Aug 8.

21.

Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN.

de Giorgio A, Krell J, Harding V, Stebbing J, Castellano L.

Mol Cell Biol. 2013 Oct;33(20):3976-82. doi: 10.1128/MCB.00683-13. Epub 2013 Aug 5. Review.

22.

The p53 miRNA interactome and its potential role in the cancer clinic.

Krell J, Frampton AE, Colombo T, Gall TM, De Giorgio A, Harding V, Stebbing J, Castellano L.

Epigenomics. 2013 Aug;5(4):417-28. doi: 10.2217/epi.13.41. Review.

PMID:
23895654
23.

Gallery. Medical illustrations.

Edwards A, Dickie D, Culley J, Kakiziba Z, Harding V, Bishop D, Goerner C.

J Vis Commun Med. 2013 Jun;36(1-2):44-7. doi: 10.3109/17453054.2013.790008. No abstract available.

PMID:
23641766
24.

Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer.

Harding V, Fenu E, Medani H, Shaboodien R, Ngan S, Li HK, Burt R, Diamantis N, Tuthill M, Blagden S, Gabra H, Urch CE, Moser S, Agarwal R.

Br J Cancer. 2012 Sep 4;107(6):925-30. doi: 10.1038/bjc.2012.343. Epub 2012 Aug 9.

25.

Embolization of uterine arteriovenous malformations in patients with gestational trophoblastic tumors: a review of patients at Charing Cross Hospital, 2000-2009.

McGrath S, Harding V, Lim AK, Burfitt N, Seckl MJ, Savage P.

J Reprod Med. 2012 Jul-Aug;57(7-8):319-24.

PMID:
22838248
26.

Nonmelanoma skin cancers among HIV-infected persons in the HAART era.

Garlassi E, Harding V, Weir J, Francis N, Nelson M, Newsom-Davis T, Bower M.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):e63-5. doi: 10.1097/QAI.0b013e318251b004. No abstract available.

PMID:
22622078
27.

Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia.

Agarwal R, Harding V, Short D, Fisher RA, Sebire NJ, Harvey R, Patel D, Savage PM, Lim AK, Seckl MJ.

Br J Cancer. 2012 Mar 13;106(6):1089-94. doi: 10.1038/bjc.2012.65. Epub 2012 Feb 28.

28.

Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer.

Li HK, Harding V, Williamson R, Blagden S, Gabra H, Agarwal R.

J Clin Oncol. 2012 Jan 10;30(2):e19-20. doi: 10.1200/JCO.2011.38.1426. Epub 2011 Dec 12. No abstract available.

PMID:
22162572
29.

Controlling a complex metropolis, 1650-1750: politics, parishes and powers.

Harding V.

Lond J. 2001;26(1):29-37. No abstract available.

PMID:
18782933
30.

Signal peptidase I-mediated processing of an engineered mammalian cytochrome b(5) precursor is an exocytoplasmic post-translocational event in Escherichia coli.

Kaderbhai NN, Harding V, Kaderbhai MA.

Mol Membr Biol. 2008 Aug;25(5):388-99. doi: 10.1080/09687680802154799.

PMID:
18651317
31.

A comparison of methods for shoulder strength assessment and analysis of Constant score change in patients aged over fifty years in the United Kingdom.

Walton MJ, Walton JC, Honorez LA, Harding VF, Wallace WA.

J Shoulder Elbow Surg. 2007 May-Jun;16(3):285-9. Epub 2007 Feb 22.

PMID:
17321154
32.

Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure.

Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA.

Proc Natl Acad Sci U S A. 2001 May 8;98(10):5809-14. Epub 2001 May 1.

33.

Inpatient vs. outpatient pain management: results of a randomised controlled trial.

Williams AC, Richardson PH, Nicholas MK, Pither CE, Harding VR, Ridout KL, Ralphs JA, Richardson IH, Justins DM, Chamberlain JH.

Pain. 1996 Jul;66(1):13-22.

PMID:
8857627
34.

Sheep pancreatic microsomes as an alternative to the dog source for studying protein translocation.

Kaderbhai MA, Harding VJ, Karim A, Austen BM, Kaderbhai NN.

Biochem J. 1995 Feb 15;306 ( Pt 1):57-61.

35.

Processing and glycosylation of preproteins by sheep pancreatic microsomes.

Kaderbhai MA, Harding V, Karim A, Kaderbhai NN.

Biochem Soc Trans. 1995 Feb;23(1):98S. No abstract available.

PMID:
7758818
36.

Over-production and isolation of a precursor protein in a form ideal as a substrate for leader peptidase.

Kaderbhai NN, Harding VJ, Kaderbhai MA.

Biochem Soc Trans. 1995 Feb;23(1):58S. No abstract available.

PMID:
7758773
37.

The development of a battery of measures for assessing physical functioning of chronic pain patients.

Harding VR, Williams AC, Richardson PH, Nicholas MK, Jackson JL, Richardson IH, Pither CE.

Pain. 1994 Sep;58(3):367-75.

PMID:
7838586
38.

Closing the audit loop: a patient satisfaction survey.

Harding LK, Griffith J, Harding VM, Tulley NJ, Notghi A, Thomson WH.

Nucl Med Commun. 1994 Apr;15(4):275-8.

PMID:
8072740
39.

The effects of a cognitive-behavioral pain management programme on the quality of work and employment status of severely impaired chronic pain patients.

Richardson IH, Richardson PH, Williams AC, Featherstone J, Harding VR.

Disabil Rehabil. 1994 Jan-Mar;16(1):26-34.

PMID:
8136507
40.

Evaluation of a cognitive behavioural programme for rehabilitating patients with chronic pain.

Williams AC, Nicholas MK, Richardson PH, Pither CE, Justins DM, Chamberlain JH, Harding VR, Ralphs JA, Jones SC, Dieudonné I, et al.

Br J Gen Pract. 1993 Dec;43(377):513-8.

42.

Efficient bacterial export of a eukaryotic cytoplasmic cytochrome.

Karim A, Kaderbhai N, Evans A, Harding V, Kaderbhai MA.

Biotechnology (N Y). 1993 May;11(5):612-8.

PMID:
7763609
43.

An examination of the 'wet dog' shake behaviour in rats produced by acute administration of sodium n-dipropylacetate.

Fletcher A, Harding V.

J Pharm Pharmacol. 1981 Dec;33(12):811-3. No abstract available.

PMID:
6121863
44.

The importance of play for children in hospital.

Harding V.

Nurs Mirror Midwives J. 1977 Jan 20;144(3):46-8. No abstract available.

PMID:
325540
45.

Let's make a game of it.

Harding V, Walker S.

Nurs Mirror Midwives J. 1972 Dec 22;135(25):14-7. No abstract available.

PMID:
4485667
46.

A method of evaluating osseous development from birth to 14 years.

HARDING VS.

Child Dev. 1952 Dec;23(4):247-71. No abstract available.

PMID:
13042892
47.

Time schedule for the appearance and fusion of a second accessory center of ossification of the calcaneus.

HARDING VV.

Child Dev. 1952 Sep;23(3):180-4. No abstract available.

PMID:
12998088
48.

Serum standards for serologic tests for syphilis.

HARRIS A, HARDING VL, BOSSAK HN.

J Vener Dis Inf. 1951 Nov;32(11):310-8. No abstract available.

PMID:
14874327
49.

The effect of temperature variants on quantitative turbidimetric determinations of spinal fluid protein, using trichloracetic acid.

HARDING VL, HARRIS A.

J Vener Dis Inf. 1949 Nov;30(11):325-7. No abstract available.

PMID:
18144106
50.

A macroflocculation spinal fluid test employing cardiolipin-lecithin antigen.

ROSENBERG AA, HARRIS A, HARDING VL.

J Vener Dis Inf. 1948 Dec;29(12):359-61. No abstract available.

PMID:
18895279

Supplemental Content

Loading ...
Support Center